Cancer Cell-Targeted siRNA Delivery by Folate-Conjugated Gold-siRNA-PEG/PEI Nanop
Cancer Cell-Targeted siRNA Delivery by Folate-Conjugated Gold-siRNA-PEG/PEI Nanop
批准号:
7980323
负责人:
Faqing Huang
金额:
$43.5万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-06-30
关键词:
A549AffectApoptosisAreaCancer Cell GrowthCancer cell lineCell DeathCell divisionCell membraneCell physiologyCellsCervicalCessation of lifeChemistryDendrimersDevelopmentDown-RegulationEndocytosisEssential GenesFigs - dietaryFolateFolic AcidGene DeliveryGene ExpressionGene TargetingGenesGoldHeart DiseasesHela CellsHigh Pressure Liquid ChromatographyHumanHydrolysisIn VitroIndividualInhibition of ApoptosisInhibition of Cancer Cell GrowthInvestigationKB CellsLabelLeadLifeLipofectamineLiposomesLuc GeneLuciferasesLungMalignant NeoplasmsMediatingMethodsMolecular WeightNatureNormal CellOrganismOvarianPathway interactionsPolyethylene GlycolsPolyethyleneiminePolymersPreparationPropertyProteinsRNARNA InterferenceRadioisotopesReagentResearchRibonucleasesSeriesSideSmall Interfering RNASpecificitySpectrum AnalysisStructureSystemTestingTherapeuticTimeToxic effectToxinTransfectionTransmission Electron MicroscopyUnited StatesViralViral Vectorbasecancer cellcancer therapycaspase-8cell growthcytotoxicityexpectationexperiencefolate-binding proteinfunctional genomicsgel electrophoresislight scatteringnanoparticlenext generationnovelpublic health relevancesurvivintargeted deliverytherapeutic developmenttoolzeta potential
中文摘要
描述(由申请人提供):
癌症是美国所有死亡的第二大原因,仅略高于心脏病。尽管已经显示通过siRNA下调基因表达是有效的和靶基因特异性的,但是目前还没有治疗上可接受的方法用于siRNA递送,其以高效率仅靶向癌细胞而不影响正常细胞。在拟议的研究中,我们将制备,表征和测试一种新的叶酸缀合的多组分金-siRNA纳米复合物系统,该系统允许通过叶酸受体辅助的内吞作用对纳米复合物进行癌细胞特异性递送。金-siRNA纳米复合物将从预制的金纳米颗粒和化学和酶促合成的硫代RNA和硫代RNA-PEG-叶酸缀合物逐步组装。将通过NMR、HPLC、凝胶电泳、动态光散射、zeta电位和透射电子显微镜进行广泛表征。使用不同的癌细胞系(A549,KB,HeLa和SKOV 3),我们将分析细胞内递送效率,特异性基因敲除和细胞功能研究,包括细胞生长和细胞死亡的抑制。预计拟议的研究将开发一种基于主动靶向金纳米颗粒的新siRNA递送系统。有效下调必需基因[生存素和CASP 8AP 2(半胱天冬酶8相关蛋白2,一种凋亡因子)]将导致癌细胞生长抑制和癌细胞死亡。
公共卫生相关性:
该项目将开发一种新的叶酸缀合的Au-siRNA纳米复合物系统。特异性siRNA递送至癌细胞和基因表达的有效下调将通过Au-siRNA纳米复合物实现。必需基因的敲除将导致癌细胞生长抑制和癌细胞死亡。这项研究可能会导致开发用于癌症治疗的治疗性siRNA递送系统。
英文摘要
DESCRIPTION (provided by applicant):
Cancer is the second leading course for all deaths in the United States, surpassed only slightly by heart disease. Although down-regulation of gene expression by siRNA has been shown to be both potent and target gene-specific, there is currently no therapeutically acceptable method for siRNA delivery that targets only cancer cells with high efficiency without affecting normal cells. In the proposed research, we will prepare, characterize, and test a novel folate-conjugated multicomponent gold-siRNA nanoplex system, which permits cancer cell-specific delivery of the nanoplexes through folate receptor-assisted endocytosis. The gold-siRNA nanoplex will be assembled stepwise from pre-made gold nanoparticles and chemically and enzymatically synthesized thioRNA and thioRNA-PEG-folate conjugates. Extensive characterization will be performed by NMR, HPLC, gel electrophoresis, dynamic light scattering, zeta potential, and transmission electron microscopy. Using different cancer cell lines (A549, KB, HeLa, and SKOV3), we will analyze intracellular delivery efficiency, specific gene knockdown, and cellular function studies including inhibition of cell growth and cell death. It is expected that the proposed research will develop a new siRNA delivery system based on actively targeted gold nanoparticles. Effective down-regulation of essential genes [survivin and CASP8AP2 (caspase 8 associated protein 2, an apoptosis factor)] will lead to inhibition of cancer cell growth and cancer cell death.
PUBLIC HEALTH RELEVANCE:
The proposed project will develop a novel folate-conjugated Au-siRNA nanoplex system. Specific siRNA delivery to cancer cells and efficient down-regulation of gene expression will be achieved by the Au-siRNA nanoplex. Knockdown of essential genes will cause cancer cell growth inhibition and cancer cell death. The research may lead to the development of therapeutic siRNA delivery systems for cancer treatment.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/mz200012p
发表时间:
2012-01-17
期刊:
ACS macro letters
影响因子:
7.015
作者:
[Treat NJ, Smith D, Teng C, Flores JD, Abel BA, York AW, Huang F, McCormick CL]
通讯作者:
McCormick CL
Folate Receptor-Mediated siRNA Delivery to Cancer Cells
-
批准号:7911247
-
项目类别:
-
资助金额:$12.07万
-
财政年份:2009
-
负责人:Faqing Huang
-
依托单位:
Folate Receptor-Mediated siRNA Delivery to Cancer Cells
-
批准号:7192166
-
项目类别:
-
资助金额:$16.43万
-
财政年份:2007
-
负责人:Faqing Huang
-
依托单位:
Folate Receptor-Mediated siRNA Delivery to Cancer Cells
-
批准号:7404443
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2007
-
负责人:Faqing Huang
-
依托单位:
SELECTION OF RNA WITH AATRNA SYNTHETASE ACTIVITY
-
批准号:2654913
-
项目类别:
-
资助金额:$2.0万
-
财政年份:1998
-
负责人:Faqing Huang
-
依托单位:
SELECTION OF RNA WITH AATRNA SYNTHETASE ACTIVITY
-
批准号:2021323
-
项目类别:
-
资助金额:$2.96万
-
财政年份:1997
-
负责人:Faqing Huang
-
依托单位:
海外基金